About carsgen therapeutics holdings ltd - CRTHF
CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The firm focuses on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company was founded by Zong Hai Li and Hua Mao Wang on February 9, 2018, and is headquartered in Shanghai, China.
CRTHF At a Glance
CARsgen Therapeutics Holdings Ltd.
CMC Preparation Center
Shanghai, Shanghai 200231
| Phone | N/A | Revenue | 17.48M | |
| Industry | Pharmaceuticals: Major | Net Income | -13,613,647.78 | |
| Sector | Health Technology | 2025 Sales Growth | 219.108% | |
| Fiscal Year-end | 12 / 2026 | Employees | 468 | |
| View SEC Filings |
CRTHF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 60.252 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -31.489 |
| Enterprise Value to Sales | 51.556 |
| Total Debt to Enterprise Value | 0.01 |
CRTHF Efficiency
| Revenue/Employee | 37,352.784 |
| Income Per Employee | -29,088.991 |
| Receivables Turnover | 3.866 |
| Total Asset Turnover | 0.084 |
CRTHF Liquidity
| Current Ratio | 5.734 |
| Quick Ratio | 5.699 |
| Cash Ratio | 5.468 |
CRTHF Profitability
| Gross Margin | 40.149 |
| Operating Margin | -187.203 |
| Pretax Margin | -81.892 |
| Net Margin | -77.876 |
| Return on Assets | -6.575 |
| Return on Equity | -10.624 |
| Return on Total Capital | -11.319 |
| Return on Invested Capital | -9.676 |
CRTHF Capital Structure
| Total Debt to Total Equity | 7.85 |
| Total Debt to Total Capital | 7.279 |
| Total Debt to Total Assets | 4.735 |
| Long-Term Debt to Equity | 6.202 |
| Long-Term Debt to Total Capital | 5.751 |